Cooper Co (COO) AI Stock Analysis

• Market Cap: $13.89B
• Dividend Yield: N/A
• Average Volume (3M): 2.06M
• Price to Earnings (P/E): 30.6
• Beta (1Y): 0.76
• Revenue Growth: 5.06%
• EPS Growth: -4.47%
• Country: US
• Employees: 16,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.10
• Shares Outstanding: 195,114,400
• 10 Day Avg. Volume: 2,800,144
• 30 Day Avg. Volume: 2,061,988
• PEG Ratio: -8.16
• Price to Book (P/B): 1.70
• Price to Sales (P/S): 3.42
• P/FCF Ratio: 32.24
• Enterprise Value/Market Cap: 1.16
• Enterprise Value/Revenue: 3.89
• Enterprise Value/Gross Profit: 6.06
• Enterprise Value/Ebitda: 16.81
• 1Y Price Target: $89.70
• Price Target Upside: 26.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): 4.61
• Revenue Forecast (FY): $4.32B

• Rating: 69 Neutral
• Price Target: $84.00 ▲(18.03% Upside)
• Action: Downgraded Date: 03/07/26
• Date: Action: Downgraded 03/07/26

The score is driven primarily by solid underlying fundamentals and a strong earnings update with raised EPS/FCF guidance. This is partially offset by weakening technical momentum (price below key moving averages, negative MACD) and a relatively high P/E with no dividend support.

Positive Factors

Product Portfolio & Adoption

Strong, differentiated product momentum (MyDay premium variants and MiSight myopia control) supports durable organic growth and higher-margin mix over time. Continued adoption of category-leading SKUs underpins multi-year revenue tailwinds and competitive positioning in contact lenses.

Balance Sheet Strength

Moderate leverage and a strengthening equity base provide financial flexibility for capex, targeted M&A, buybacks, and debt reduction. Stable-to-declining absolute debt lowers refinancing risk and supports multi-year investment in growth and technology without overburdening cash flow.

Free Cash Flow Generation

A materially upgraded multi-year free cash flow outlook signals sustainable internal funding for reinvestment, buybacks and debt paydown. Consistent FCF supports disciplined capital allocation and reduces reliance on external financing for strategic initiatives over the next several years.

Negative Factors

Weaker Cash Conversion

A meaningful drop in cash conversion versus prior periods reduces the company's ability to self-fund growth and return capital. If conversion remains impaired, management may need to curb buybacks or increase leverage, constraining long-term strategic flexibility and resilience to shocks.

Margin Softening

Erosion from peak gross and operating margins weakens sustainable earnings power and free cash flow. Structural mix shifts, pricing pressure or rising costs could prolong lower margins, limiting reinvestment capacity and reducing cushion against competitive or regional headwinds.

Concentrated Regional & Product Risk

Concentrated exposure in fertility equipment and specific regions creates structural downside if installations, geopolitics, or regulatory issues persist. Declines in key products like Paragard and regional softness can meaningfully depress segment growth and complicate planning over multiple quarters.

Cooper Co Business Overview & Revenue Model

Company Description

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

How the Company Makes Money

Cooper Co generates revenue through multiple key streams, including direct sales of its consumer goods through retail channels, online marketplaces, and wholesale distribution. The company also engages in strategic partnerships with major retailers and e-commerce platforms, which provide significant exposure and increased sales volume. Additionally, Cooper Co invests in brand development and marketing initiatives to enhance product visibility and consumer loyalty, thereby driving repeat purchases. The company also explores licensing agreements for its products, allowing for additional revenue through royalties while expanding its market reach.

Cooper Co Financial Statement Overview

Summary

Strong and steady revenue growth with solid gross margins supports a healthy fundamental base, but the recent margin step-down and weaker cash flow conversion (lower FCF vs. prior periods) reduce the score.

Income Statement

COO shows steady top-line expansion, with annual revenue rising from $2.9B (2021) to $4.1B in TTM (Trailing-Twelve-Months), and the latest growth remaining positive. Profitability is solid with strong gross margins (~61%–67%) and mid-teens operating margins (~14%–18%), supporting consistent earnings in most years. Offsetting this, margins have softened versus the 2024 peak (lower gross/operating profitability in the latest periods), and 2021 net income appears unusually high relative to revenue, which reduces comparability of the trendline.

Balance Sheet

The balance sheet looks generally healthy: leverage is moderate with debt-to-equity around ~0.30 in TTM (Trailing-Twelve-Months) and equity building over time (about $6.9B in 2021 to $8.4B TTM). Total debt has been fairly stable to slightly down recently (from ~$2.78B in 2025 to ~$2.50B TTM), which is supportive. The main drawback is that returns on equity are modest in recent periods (~4%–5%), suggesting the company is not converting its capital base into high shareholder returns right now.

Cash Flow

Cash generation is positive, with operating cash flow of ~$605M and free cash flow of ~$333M in TTM (Trailing-Twelve-Months). However, cash flow quality has weakened recently: free cash flow declined sharply in TTM (Trailing-Twelve-Months) and operating cash flow covers a smaller portion of reported earnings than in prior years. Free cash flow relative to net income is moderate (roughly ~55% TTM), indicating profits are not fully translating into free cash at the same strength seen in better periods.

Breakdown	TTM	Oct 2025	Oct 2024	Oct 2023	Oct 2022	Oct 2021
Income Statement
Total Revenue	4.15B	4.09B	3.90B	3.59B	3.31B	2.92B
Gross Profit	2.67B	2.48B	2.60B	2.36B	2.14B	1.96B
EBITDA	962.00M	1.05B	1.07B	885.90M	878.70M	823.90M
Net Income	401.40M	374.90M	392.30M	294.20M	385.80M	2.94B
Balance Sheet
Total Assets	12.42B	12.39B	12.32B	11.66B	11.49B	9.61B
Cash, Cash Equivalents and Short-Term Investments	124.90M	110.60M	107.60M	120.90M	138.20M	95.90M
Total Debt	2.50B	2.78B	2.58B	2.57B	2.76B	1.48B
Total Liabilities	4.06B	4.16B	4.23B	4.11B	4.32B	2.66B
Stockholders Equity	8.36B	8.24B	8.08B	7.55B	7.17B	6.94B
Cash Flow
Free Cash Flow	491.20M	433.70M	288.10M	215.00M	450.40M	524.20M
Operating Cash Flow	866.40M	796.10M	709.30M	607.50M	692.40M	738.60M
Investing Cash Flow	-379.00M	-372.90M	-764.60M	-449.00M	-1.83B	-450.30M
Financing Cash Flow	-477.20M	-425.90M	39.20M	-173.90M	1.19B	-311.40M

Cooper Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 71.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COO, the sentiment is Negative. The current price of 71.17 is below the 20-day moving average (MA) of 78.55, below the 50-day MA of 80.55, and below the 200-day MA of 74.58, indicating a bearish trend. The MACD of -2.97 indicates Positive momentum. The RSI at 27.81 is Positive, neither overbought nor oversold. The STOCH value of 14.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COO.

Cooper Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WST	72 Outperform	$17.21B	40.29	16.68%	0.32%	4.90%	-0.26%
COO	69 Neutral	$13.89B	30.60	4.83%	―	5.06%	-4.47%
HOLX	66 Neutral	$16.78B	23.34	11.01%	―	1.74%	-25.29%
ATR	65 Neutral	$8.00B	20.41	14.67%	1.50%	2.50%	25.05%
MASI	63 Neutral	$9.19B	-45.07	-17.21%	―	-16.03%	-813.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAX	46 Neutral	$8.79B	―	-13.78%	2.75%	-21.20%	-325.40%

Cooper Co Corporate Events

Cooper Co Amends Loan Facilities to Enhance Flexibility

On February 3, 2026, The Cooper Companies, Inc. amended its 2021 Term Loan Agreement by extending the maturity date of $950 million of its term loans to February 3, 2031 while leaving the $550 million balance unchanged, removing the credit spread adjustment, increasing the cap on incremental term loans to the greater of $1.365 billion and 100% of consolidated EBITDA, and allowing loan pricing to be based either on the company’s senior unsecured long-term debt ratings or its consolidated net indebtedness to consolidated EBITDA ratio. On the same date, the company and CooperVision International Limited executed an amendment to their 2024 Revolving Credit Agreement to align its terms with the revised 2021 loan facility, including removal of credit spread adjustments, a move that streamlines Cooper’s capital structure, provides greater flexibility for additional borrowing, and could enhance its long-term funding stability and financial planning capacity for stakeholders.

The most recent analyst rating on (COO) stock is a Buy with a $99.00 price target. To see the full list of analyst forecasts on Cooper Co stock, see the COO Stock Forecast page.

Cooper Co strikes board-refresh pact with Browning West

On December 22, 2025, CooperCompanies entered into a cooperation agreement with investment firm Browning West, under which the company appointed veteran medical device executive Walter M. Rosebrough Jr. to its board and its Corporate Governance and Nominating Committee, effective January 3, 2026. The deal commits Cooper to supporting Rosebrough’s election at the 2026 annual meeting, conducting a Browning West–approved search for an additional independent director with medical technology experience by June 30, 2026, capping the board at ten members during the agreement term, and giving due consideration to naming Rosebrough board chair by the end of 2026, while Browning West agrees to standstill and voting commitments, including backing the company’s full slate in 2026. The move, announced in a December 23, 2025 press release, effectively aligns Cooper with an influential shareholder, brings in a director with a strong track record of value creation in the medical device sector, and signals further board refreshment aimed at strengthening governance and supporting long-term shareholder value.

The most recent analyst rating on (COO) stock is a Hold with a $88.00 price target. To see the full list of analyst forecasts on Cooper Co stock, see the COO Stock Forecast page.